1 / 11

Abuse Liability of Hydromorphone Extended Release Capsules

Abuse Liability of Hydromorphone Extended Release Capsules. Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research Food and Drug Administration ALSDAC September 10, 2003. Hydromorphone Formulations.

lucita
Download Presentation

Abuse Liability of Hydromorphone Extended Release Capsules

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research Food and Drug Administration ALSDAC September 10, 2003

  2. Hydromorphone Formulations • Immediate release tablets (Dilaudid 2, 4 and 8 mg), injectable (1, 2, 4 and 10 mg/ml), oral solution (5 mg/5ml) and suppositories (3 mg) have been marketed in the United States for many years • Extended release formulations marketed in the UK and Canada for once or twice a day use • Palladone represents a new extended release formulation under FDA review CSS/CDER ALSDAC September 9-10, 2003

  3. Palladone CapsulesProposed • Strengths: 12 mg, 16 mg, 24 mg and 32 mg • Boxed Warning: For use only in opioid tolerant patients • Indication: For the management of chronic moderate to severe pain in patients requiring continuous around the clock opioid analgesia for an extended period of time • Dosage: Once a day CSS/CDER ALSDAC September 9-10, 2003

  4. Hydromorphone as Schedule II (CII) • High abuse potential • Highest level of control for an approved drug • Prescriber and dispenser registration, separate record-keeping by dispenser, distribution order forms, no refills, manufacturing security and quotas, import and export permits CSS/CDER ALSDAC September 9-10, 2003

  5. abuse potential+social and public health factors Abuse Liability CSS/CDER ALSDAC September 9-10, 2003

  6. Hydromorphone’s Relative Potency • Physiological Opioid Effects - analgesia, miosis, respiratory depression: • 4 times more potent than oxycodone and morphine (oral route) • 6-7 times more potent than morphine (intravenous route) • Subjective Opioid Effects - euphoria and drug liking: • 10 times more potent than morphine (oral or intravenous routes) (Jasinski et al., 1977; Hill and Zacny, 2000) CSS/CDER ALSDAC September 9-10, 2003

  7. History of Hydromorphone Abuse • Hydromorphone abuse dates back to 1970s • In 2002, DEA field offices reported that 4 mg hydromorphone tablets (Dilaudid) street price averaged $40/tablet CSS/CDER ALSDAC September 9-10, 2003

  8. Drug Abuse Related Deaths DAWN-Medical Examiners • For 1999-2001 period: • 132 hydromorphone-related deaths 7.5 deaths/100,000 Rx • 1,272 oxycodone-related deaths 1.8 deaths/100,000 Rx 6.1 deaths/100,000 Rx - oxycodone single entity products Rx Source: IMS Health, National Prescription Audit PlusTM CSS/CDER ALSDAC September 9-10, 2003

  9. Limitations: Deaths/Prescriptions • These ratios are “crude” estimates • DAWN medical examiners deaths do not represent national estimates • DAWN medical examiner reports may include multiple drug mentions and rarely include brand names • Sales data represent the whole U.S. market • Denominators include all formulations of the drug CSS/CDER ALSDAC September 9-10, 2003

  10. Summary • Based upon the data reviewed, hydromorphone appears to have higher abuse liability than other Schedule II opioids • When compared to immediate release hydromorphone products currently available, Palladone has higher potential risks of misuse and overdose that might result in death • Palladone poses significant risks of overdose in non-opioid tolerant patients or if misused and abused CSS/CDER ALSDAC September 9-10, 2003

  11. Conclusion • Risk management programs should be designed to address the risks associated with high-dose opioid analgesic drug products, such as Palladone CSS/CDER ALSDAC September 9-10, 2003

More Related